Bausch Health (BHC) Announces Global Phase 3 RED-C Clinical Program Results

Bausch Health Companies Inc. (NYSE:BHC) is one of the most undervalued Canadian stocks to buy according to hedge funds. On January 23, Bausch Health announced the results of its global Phase 3 RED-C clinical program, which evaluated amorphous-rifaximin solid soluble dispersion for the primary prevention of hepatic encephalopathy in adults with liver cirrhosis. The program consisted of two randomized, double-blind, placebo-controlled trials involving over 1,000 patients across 17 countries.

Although the treatment was found to be safe and well-tolerated, both clinical trials failed to meet the primary endpoint of delaying the first episode of hepatic encephalopathy in patients with no prior history of the condition. The company is now reviewing the full dataset to identify potential new development opportunities and remains committed to advancing treatments in hepatology and other therapeutic areas. Bausch Health also extended its gratitude to the patients, investigators, and research teams involved in the 398-site global study.

Earlier, on January 7, Truist analyst Les Sulewski increased the price target for Bausch Health Companies Inc. (NYSE:BHC) to $8 from $7 while maintaining a Hold rating. Sulewski highlighted that the theme of affordable medicines remains an attractive investment focus heading into 2026.

Bausch Health Companies Inc. (NYSE:BHC) operates as a diversified specialty pharmaceutical and medical device company. It develops, manufactures, and markets products in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, OTC products, aesthetic medical devices, and eye health internationally.

While we acknowledge the potential of BHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.